Increasing awareness, participation, funding and streamlining communication for MS trials.
20th May, 2013
A 16 year follow-up of patients from the original interferon-beta-1b clinical trial shows that those who received interferon early do better on measures of
11th April, 2013
Results of a phase II trial of daclizumab in relapsing remitting MS have been published and show promising effects in reducing relapse rates.